Immuneering
MA - CambridgeBiotechnology
Focus: Immuneering is a Cambridge-based biotech focused on bioinformatics for genomics in oncology, currently advancing multiple programs through Phase 1-3 development.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Open Jobs
3
Should You Work at Immuneering?
AI assessmentImmuneering offers specialized oncology biotech exposure but carries early-stage financial opacity and limited hiring velocity; best for risk-tolerant candidates seeking genomics depth over near-term career security.
Why Work Here
- Access to early-stage oncology programs including a Phase 3 asset (Atebimetinib for pancreatic cancer), offering meaningful exposure to clinical development trajectory.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IMM-1-104 Monotherapy
Advanced Solid TumorClinical Trials (1)
NCT05585320A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Phase 1/2Help build intelligence for Immuneering
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.